Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
22
AVXL Quote, Financials, Valuation and Earnings
Last price:
$3.72
Seasonality move
:
3.46%
Day range:
$3.65 - $3.80
52-week range:
$2.86 - $14.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.50x
Volume:
2.1M
Avg. volume:
3.8M
1-year change:
-65.78%
Market cap:
$331.9M
Revenue:
--
EPS (TTM):
-$0.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AVXL
Anavex Life Sciences Corp.
|
-- | -$0.15 | -- | -22.97% | $22.00 |
|
ADMA
ADMA Biologics, Inc.
|
$130.5M | $0.16 | 18.97% | -56.04% | $25.67 |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-- | -$0.16 | -- | -44.74% | $9.67 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$58.7M | -- | 11.45% | -- | $11.75 |
|
VSTM
Verastem, Inc.
|
$5.8M | -$0.61 | -88.84% | -63.78% | $16.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AVXL
Anavex Life Sciences Corp.
|
$3.72 | $22.00 | $331.9M | -- | $0.00 | 0% | -- |
|
ADMA
ADMA Biologics, Inc.
|
$19.53 | $25.67 | $4.6B | 22.93x | $0.00 | 0% | 9.83x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$5.29 | $9.67 | $318M | -- | $0.00 | 0% | -- |
|
CRMD
CorMedix, Inc.
|
$12.19 | $19.00 | $960.4M | 5.94x | $0.00 | 0% | 4.10x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$6.91 | $11.75 | $408.4M | -- | $0.00 | 0% | 1.91x |
|
VSTM
Verastem, Inc.
|
$7.87 | $16.00 | $592.8M | -- | $0.00 | 0% | 36.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AVXL
Anavex Life Sciences Corp.
|
-- | -0.800 | -- | 11.47x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
23.99% | 1.936 | 4.95% | 2.64x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | 0.085 | 3.7% | 2.92x |
|
VSTM
Verastem, Inc.
|
121% | -1.113 | 15.18% | 2.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AVXL
Anavex Life Sciences Corp.
|
-- | -$10.8M | -44.87% | -44.87% | -- | -$8.6M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-$63.7K | -$8M | -53.75% | -66.61% | -- | -$7M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
|
VSTM
Verastem, Inc.
|
$9.3M | -$40.7M | -369.69% | -1773.4% | -362.17% | -$44.5M |
Anavex Life Sciences Corp. vs. Competitors
-
Which has Higher Returns AVXL or ADMA?
ADMA Biologics, Inc. has a net margin of -- compared to Anavex Life Sciences Corp.'s net margin of 27.14%. Anavex Life Sciences Corp.'s return on equity of -44.87% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences Corp.-- -$0.11 $94.9M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About AVXL or ADMA?
Anavex Life Sciences Corp. has a consensus price target of $22.00, signalling upside risk potential of 489.81%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 31.69%. Given that Anavex Life Sciences Corp. has higher upside potential than ADMA Biologics, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences Corp.2 1 0 ADMAADMA Biologics, Inc.3 0 0 -
Is AVXL or ADMA More Risky?
Anavex Life Sciences Corp. has a beta of 1.155, which suggesting that the stock is 15.531% more volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.
-
Which is a Better Dividend Stock AVXL or ADMA?
Anavex Life Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences Corp. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or ADMA?
Anavex Life Sciences Corp. quarterly revenues are --, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Anavex Life Sciences Corp.'s net income of -$9.8M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Anavex Life Sciences Corp.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 22.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences Corp. is -- versus 9.83x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences Corp.-- -- -- -$9.8M ADMAADMA Biologics, Inc.9.83x 22.93x $134.2M $36.4M
-
Which has Higher Returns AVXL or ALDX?
Aldeyra Therapeutics, Inc. has a net margin of -- compared to Anavex Life Sciences Corp.'s net margin of --. Anavex Life Sciences Corp.'s return on equity of -44.87% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences Corp.-- -$0.11 $94.9M ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M -
What do Analysts Say About AVXL or ALDX?
Anavex Life Sciences Corp. has a consensus price target of $22.00, signalling upside risk potential of 489.81%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 91.42%. Given that Anavex Life Sciences Corp. has higher upside potential than Aldeyra Therapeutics, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than Aldeyra Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences Corp.2 1 0 ALDXAldeyra Therapeutics, Inc.4 0 0 -
Is AVXL or ALDX More Risky?
Anavex Life Sciences Corp. has a beta of 1.155, which suggesting that the stock is 15.531% more volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.879%.
-
Which is a Better Dividend Stock AVXL or ALDX?
Anavex Life Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences Corp. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or ALDX?
Anavex Life Sciences Corp. quarterly revenues are --, which are smaller than Aldeyra Therapeutics, Inc. quarterly revenues of --. Anavex Life Sciences Corp.'s net income of -$9.8M is lower than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, Anavex Life Sciences Corp.'s price-to-earnings ratio is -- while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences Corp. is -- versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences Corp.-- -- -- -$9.8M ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M
-
Which has Higher Returns AVXL or CRMD?
CorMedix, Inc. has a net margin of -- compared to Anavex Life Sciences Corp.'s net margin of 49.9%. Anavex Life Sciences Corp.'s return on equity of -44.87% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences Corp.-- -$0.11 $94.9M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About AVXL or CRMD?
Anavex Life Sciences Corp. has a consensus price target of $22.00, signalling upside risk potential of 489.81%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 55.87%. Given that Anavex Life Sciences Corp. has higher upside potential than CorMedix, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than CorMedix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences Corp.2 1 0 CRMDCorMedix, Inc.4 0 0 -
Is AVXL or CRMD More Risky?
Anavex Life Sciences Corp. has a beta of 1.155, which suggesting that the stock is 15.531% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock AVXL or CRMD?
Anavex Life Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences Corp. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or CRMD?
Anavex Life Sciences Corp. quarterly revenues are --, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Anavex Life Sciences Corp.'s net income of -$9.8M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Anavex Life Sciences Corp.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences Corp. is -- versus 4.10x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences Corp.-- -- -- -$9.8M CRMDCorMedix, Inc.4.10x 5.94x $104.3M $108.6M
-
Which has Higher Returns AVXL or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of -- compared to Anavex Life Sciences Corp.'s net margin of -40.15%. Anavex Life Sciences Corp.'s return on equity of -44.87% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences Corp.-- -$0.11 $94.9M VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About AVXL or VNDA?
Anavex Life Sciences Corp. has a consensus price target of $22.00, signalling upside risk potential of 489.81%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 70.04%. Given that Anavex Life Sciences Corp. has higher upside potential than Vanda Pharmaceuticals, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than Vanda Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences Corp.2 1 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is AVXL or VNDA More Risky?
Anavex Life Sciences Corp. has a beta of 1.155, which suggesting that the stock is 15.531% more volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.
-
Which is a Better Dividend Stock AVXL or VNDA?
Anavex Life Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences Corp. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or VNDA?
Anavex Life Sciences Corp. quarterly revenues are --, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Anavex Life Sciences Corp.'s net income of -$9.8M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Anavex Life Sciences Corp.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences Corp. is -- versus 1.91x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences Corp.-- -- -- -$9.8M VNDAVanda Pharmaceuticals, Inc.1.91x -- $56.3M -$22.6M
-
Which has Higher Returns AVXL or VSTM?
Verastem, Inc. has a net margin of -- compared to Anavex Life Sciences Corp.'s net margin of -876.34%. Anavex Life Sciences Corp.'s return on equity of -44.87% beat Verastem, Inc.'s return on equity of -1773.4%.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences Corp.-- -$0.11 $94.9M VSTMVerastem, Inc.82.57% -$1.35 $74M -
What do Analysts Say About AVXL or VSTM?
Anavex Life Sciences Corp. has a consensus price target of $22.00, signalling upside risk potential of 489.81%. On the other hand Verastem, Inc. has an analysts' consensus of $16.00 which suggests that it could grow by 103.3%. Given that Anavex Life Sciences Corp. has higher upside potential than Verastem, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than Verastem, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences Corp.2 1 0 VSTMVerastem, Inc.8 0 0 -
Is AVXL or VSTM More Risky?
Anavex Life Sciences Corp. has a beta of 1.155, which suggesting that the stock is 15.531% more volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.798%.
-
Which is a Better Dividend Stock AVXL or VSTM?
Anavex Life Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences Corp. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or VSTM?
Anavex Life Sciences Corp. quarterly revenues are --, which are smaller than Verastem, Inc. quarterly revenues of $11.2M. Anavex Life Sciences Corp.'s net income of -$9.8M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Anavex Life Sciences Corp.'s price-to-earnings ratio is -- while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences Corp. is -- versus 36.78x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences Corp.-- -- -- -$9.8M VSTMVerastem, Inc.36.78x -- $11.2M -$98.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
